Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health Cimzia Prior Auth Coverage Update | Op…
    Ask Trek AI about this page
    CurrentModa HealthPolicy M-0028

    Cimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria

    Customize your policy alerts

    Sign up for Moda Health Policy M-0028 alerts

    Get alerted when Policy M-0028 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Moda Health prior authorization, dosing limits, length of authorization, and medical necessity criteria for Cimzia (certolizumab pegol) for multiple indications (e.g., RA, Crohn's disease, PsA, AS, pJIA). Applies to providers requesting coverage for members under Moda Health plans.

    Policy Summary
    PayerModa Health
    PolicyCimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria
    Policy CodePolicy M-0028
    Change TypeNo material changes
    Effective DateMar 3, 2026
    Last ReviewMar 3, 2026
    Next Review DateMar 3, 2026
    Key ActionObtain prior authorization with documentation of baseline objective disease severity, required prior therapy trials or contraindications, and required pre-treatment screening (HBV and latent TB) before initiating Cimzia.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    180dinitial prior authorization duration
    365drenewal prior authorization duration
    400common per-dose max
    ≥2y

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    pJIA min age
    200mgcommon maintenance dose

    Coverage Criteria and Clinical Requirements

    Universal Criteria

    Covered when ALL of the following universal criteria are met:

    Universal prerequisites: Site-of-care specialty infusion program requirements are met; member is at least 18 years of age unless specified for the indication; HBV screening completed prior to initiating treatment; provider confirms member is up to date with age-appropriate vaccinations prior to initiating therapy.

    From Initial Approval / Prior authorization validity

    Infection and vaccine screening: Latent tuberculosis (TB) screening completed prior to initiating treatment with ongoing monitoring during therapy; no active infection present; member has not received live vaccines immediately prior to treatment and will not receive live vaccines during therapy.

    Universal Criteria

    Concomitant therapy: Member is not on concurrent treatment with another biologic therapy or targeted synthetic therapy.

    Universal Criteria

    Rheumatoid Arthritis (RA)

    Covered when ALL of the following are met:

    RA baseline assessment: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active rheumatoid arthritis.

    RA requirements

    Prior therapy requirement: Either: member has had at least a 3-month trial and failed ONE conventional synthetic DMARD (e.g., methotrexate, azathioprine, sulfasalazine, leflunomide, etc.); OR member is already established on biologic or targeted synthetic therapy for RA.3 months

    RA clinical trials

    Concomitant methotrexate: Prescribed in combination with methotrexate unless the member has a contraindication or intolerance to methotrexate.

    RA prescribing

    Crohn's Disease (CD)

    Covered when ALL of the following are met:

    CD baseline assessment: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active Crohn's disease.

    CD requirements

    Prior therapy requirement: Either: documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum 3-month trial of corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate); OR evidence of high-risk disease for which corticosteroids or immunomodulators are inadequate and biologic therapy is necessary; OR member is already established on biologic or targeted synthetic therapy for CD.3 months

    CD clinical

    Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, ustekinumab SC, guselkumab, upadacitinib, risankizumab, or vedolizumab; OR member is continuing treatment.3 months

    Psoriatic Arthritis (PsA)

    Covered when ALL of the following are met:

    PsA baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active psoriatic arthritis.

    PsA requirements

    Prior therapy by phenotype: For axial disease or enthesitis: failure of at least a 4-week trial of ONE NSAID unless contraindicated; OR For peripheral arthritis or dactylitis: failure of at least a 3-month trial of ONE csDMARD; OR member is already established on biologic or targeted synthetic therapy for PsA.4 weeks (NSAID) or 3 months (csDMARD)

    PsA clinical

    Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, ustekinumab, guselkumab, tofacitinib, upadacitinib, risankizumab, or apremilast; OR member is continuing treatment.3 months

    Ankylosing Spondylitis (AS)

    Covered when ALL of the following are met:

    AS baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented active ankylosing spondylitis.

    AS requirements

    NSAID trial requirement: Either: member had an adequate trial and failure of at least TWO NSAIDs over 4 weeks in total, unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for AS.2 NSAID trials over 4 weeks

    AS clinical

    Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, upadacitinib, or tofacitinib; OR member is continuing treatment.3 months

    Commercial step therapy for AS

    Polyarticular Juvenile Idiopathic Arthritis (pJIA)

    Covered when ALL of the following are met:

    Age requirement: Member is at least 2 years of age.age >= 2 years

    pJIA age

    pJIA baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active polyarticular juvenile idiopathic arthritis.

    pJIA requirements

    Prior therapy requirement: Either: member has had at least a 1-month trial and failure (unless contraindicated or intolerant) of prior therapy with either oral NSAIDs OR csDMARDs (e.g., methotrexate, leflunomide, sulfasalazine); OR member is already established on biologic or targeted synthetic therapy for pJIA.1 month

    pJIA prior therapy

    General Commercial/Medicaid prior trial requirement (select indications)

    Covered when ALL of the following are met for specified member types

    trial_requirement: Member has tried and had inadequate response, contraindication, or intolerance to at least a 3-month trial of a specified alternative agent (lists differ for Commercial vs Medicaid) OR member is continuing treatment.3 months

    See indication-specific lists in other criteria

    Polyarticular Juvenile Idiopathic Arthritis (pJIA) — Initial Therapy

    Covered when ALL of the following are met

    age_and_assessment: Member is at least 2 years of age AND physician has assessed baseline disease severity using an objective measure/tool AND documented moderate to severe active polyarticular disease.age >= 2 years
    prior_therapy_or_established: EITHER member had at least a 1-month trial and failure (unless contraindicated or intolerant) of previous therapy with either oral NSAIDs OR csDMARDs (e.g., methotrexate, leflunomide, sulfasalazine) OR member is already established on biologic or targeted synthetic therapy for pJIA.1 month for NSAID/csDMARD trial

    Non-radiographic Axial Spondyloarthritis (nr-axSpA) — Initial Therapy

    Covered when ALL of the following are met

    objective_inflammation_and_imaging: Physician has assessed baseline disease severity with an objective tool AND objective signs of inflammation (e.g., elevated CRP above the upper limit of normal and/or sacroiliitis on MRI) AND no definitive radiographic structural damage on sacroiliac joints.CRP above ULN or MRI sacroiliitis
    prior_nsaid_or_established: EITHER member had an adequate trial and failure of at least TWO NSAIDs unless contraindicated OR member is already established on biologic or targeted synthetic therapy for nr-axSpA.2 NSAID trials

    Plaque Psoriasis (PsO) — Initial Therapy

    Covered when ALL of the following are met

    disease_severity: Physician has assessed baseline disease severity AND documented moderate to severe plaque psoriasis for at least 6 months with at least one of: BSA ≥10% OR PASI ≥10 OR incapacitating/serious emotional consequences or intractable pruritis.>=6 months disease duration
    prior_therapies: Member did not respond adequately (or is not a candidate) to: a 4-week minimum trial of topical agents; AND a 3-month minimum trial of at least ONE non-biologic systemic agent; AND a 3-month minimum trial of phototherapy (PUVA or UVB); unless member is already established on biologic/targeted therapy or has >10% BSA involvement.topicals 4 weeks; systemic 3 months; phototherapy 3 months

    Note: members ≤90 kg should initiate lower maintenance dosing regimen.

    Immune Checkpoint Inhibitor-Related Toxicities

    Compendia-recommended use covered when ALL of the following are met

    ici_inflammatory_arthritis: Member has been receiving immune checkpoint inhibitor therapy AND has moderate or severe immunotherapy-related inflammatory arthritis AND is unable to taper corticosteroids after one week.unable to taper after 1 week

    Compendia recommended indication

    Renewal / Response Criteria (by indication)

    Authorization renewal requires documented disease response compared to baseline using indication-specific objective measures

    RA_response: Rheumatoid Arthritis: improvement in signs/symptoms vs baseline (e.g., tender/swollen joint counts, CRP, patient global), or improvement on a disease activity scoring tool (e.g., DAS28 improvement ≥1.2 or ACR20 ≥20%).DAS28 improvement >=1.2 or ACR20 >=20%
    CD_response: Crohn's Disease: improvement in signs/symptoms vs baseline (e.g., endoscopic activity, stools, abdominal pain, weight regain, hematocrit, biomarkers like fecal calprotectin or CRP, or Harvey-Bradshaw Index).clinical and/or biomarker improvement
    PsA_response: Psoriatic Arthritis: improvement in tender/swollen joint counts, CRP, patient global, imaging changes, or disease activity scoring tool.clinical or imaging improvement

    Polyarticular Juvenile Idiopathic Arthritis (pJIA) — disease response definition

    Covered when disease response is demonstrated as follows:

    pJIA response criteria: Improvement in signs and symptoms compared to baseline such as number of tender and swollen joint counts, reduction in C-reactive protein, improvement in patient global assessment, and/or improvement on a disease activity scoring tool (e.g., JADAS or ACR‑Pedi 30 with at least 30% improvement from baseline in three of six variables).ACR-Pedi 30 or equivalent

    Non-radiographic Axial Spondyloarthritis (nr-axSpA) — disease response definition

    Covered when disease response is demonstrated as follows:

    nr-axSpA response criteria: Improvement in signs and symptoms compared to baseline such as total back pain, physical function, reduction of CRP, and/or improvement on a disease activity scoring tool (e.g., ≥1.1 improvement on ASDAS, ASDAS‑MI, ≥2 improvement on BASDAI, improvement in ASQoL, or ASAS40 response).ASDAS ≥1.1 or ASAS40

    Plaque Psoriasis (PsO) — disease response and dose escalation conditions

    Covered when disease response is demonstrated and dosing milestones met; dose escalation allowed on case-by-case basis when below criteria met:

    PsO initial response and escalation prerequisites: Improvement in signs and symptoms compared to baseline (e.g., redness, thickness, scaliness, BSA ≤1%, PASI ≤3, PGA ≤1); AND shown initial response to therapy; AND received three loading doses at the specified dose/interval; AND received a minimum of one maintenance dose at the specified dose/interval; AND responded by treatment week 6 with subsequent loss of response to justify escalation.PASI ≤3 or PGA ≤1 or BSA ≤1%

    Dose escalation limited to maximum dose/frequency specified in dosing section.

    Dosing/Administration — loading and maintenance schedules

    Dosing schedules by indication:

    Typical adult loading/maintenance: Loading: 400 mg subcutaneously at weeks 0, 2, and 4; Maintenance: 200 mg subcutaneously every other week thereafter (or 400 mg every 4 weeks). Note: 400 mg doses are administered as two 200 mg injections.400 mg loading; 200 mg Q2W maintenance
    PsA and pediatric dosing: PsA: Loading 400 mg at weeks 0, 2, and 4; then maintenance 200 mg every other week (or 400 mg every 4 weeks). Pediatric polyarticular dosing by weight bands: 10–<20 kg: loading 100 mg then maintenance 50 mg Q2W; 20–<40 kg: loading 200 mg then maintenance 100 mg Q2W; ≥40 kg: loading 400 mg then maintenance 200 mg Q2W. Note: no formulation for self-administration below 200 mg; doses <200 mg require administration by a health care professional using the vial kit.weight-based pediatric dosing as specified
    Management of immune checkpoint inhibitor-related toxicity: Dose: 200 mg subcutaneously every other week (or 400 mg every 4 weeks) up to a single 400 mg dose as indicated.

    Diagnosis-code based coverage

    Covered when the member has one of the ICD-10 diagnosis codes listed in Appendix 1

    Appendix 1 diagnosis match: Member's submitted diagnosis must be one of the ICD-10 codes listed in Appendix 1 of the policy.

    Appendix contains extensive list of RA, juvenile arthritis, ankylosing spondylitis and related codes; see full appendix for code-specific entries

    Patients must not have an active infection at the time of initiation and providers must confirm the member has not received live vaccines immediately prior to treatment and will not receive live vaccines during therapy. Initiation should be deferred until infections are resolved and vaccine timing is appropriate per the universal screening requirements.

    Coverage is not allowed for members who are receiving concurrent treatment with another biologic therapy or a targeted synthetic therapy. Prior authorization requires confirmation the member is not on overlapping biologic/targeted synthetic agents.

    When a phototherapy trial is part of the prior-therapy requirement for plaque psoriasis, members with listed contraindications to phototherapy (for example, xeroderma pigmentosum, certain photosensitive genodermatoses, pregnancy/lactation for PUVA, lupus erythematosus, prior photosensitivity disorders or history of skin cancer, immunosuppression post-transplant, severe liver/renal/cardiac disease for PUVA, young age <12 years for PUVA, or anatomic locations ineligible for phototherapy) are exempt from the phototherapy trial and will be reviewed on a case‑by‑case basis.

    There is no Cimzia formulation that permits self‑administration for doses below 200 mg. Any ordered dose less than 200 mg requires administration by a health care professional using the vial kit in an appropriate clinical setting.

    Medicare Part B covered diagnosis codes for Cimzia are listed as N/A in this policy. Where Medicare NCDs, LCDs, or LCAs exist, those CMS policies and contractor-specific guidance take precedence and may change coverage determinations for Medicare members.

    Use of Cimzia without documented pre‑treatment screening and verification is not consistent with medical necessity. Providers must document HBV screening, completion of latent TB screening with ongoing monitoring, and up‑to‑date age‑appropriate vaccination status prior to initiation; absence of these verifications would not meet medical necessity.

    Billing, Codes, and Authorization Durations

    HCPCS unit dosing limitsHCPCS
    400 billable unitsManagement of Immune Checkpoint Inhibitor-Related Toxicities — 1 dose; Plaque Psoriasis every other week; Loading doses for pJIA and other indications
    200 billable unitspJIA maintenance dose every other week
    400 billable units every 4 weeksMaintenance dose for all other indications
    HCPCS CodeHCPCS
    J0717Injection, certolizumab pegol, 1 mg; 1 billable unit = 1 mg
    NDCsNDC
    50474-0700xxCimzia 200 mg single-dose vials, lyophilized powder for reconstitution (carton of 2)
    50474-0750-xxCimzia 200 mg/mL single-dose prefilled syringe (carton of 1)
    50474-0710-xxCimzia 200 mg/mL single-dose prefilled syringes (carton of 2) and starter kit (carton of 6)
    Covered ICD-10 Codes (Appendix 1)ICD-10Covered
    K50.00Crohn's disease of small intestine without complications
    K50.011Crohn's disease of small intestine with rectal bleeding
    K50.012Crohn's disease of small intestine with intestinal obstruction
    K50.013Crohn's disease of small intestine with fistula
    K50.014Crohn's disease of small intestine with abscess
    K50.018Crohn's disease of small intestine with other complication
    K50.019Crohn's disease of small intestine with unspecified complications
    K50.10Crohn's disease of large intestine without complications
    K50.111Crohn's disease of large intestine with rectal bleeding
    K50.112Crohn's disease of large intestine with intestinal obstruction
    1–10 of 184
    1/19
    Initial prior authorization duration — inv-29: 180 days
    Initial prior authorization duration180 days (6 months)
    ApplicabilityInitial prior authorization validity provided for 6 months unless otherwise specified
    Special-case noteManagement of Immune Checkpoint Inhibitor-Related Toxicities: prior authorization validity may NOT be renewed
    Renewal prior authorization duration — inv-30: 365 days
    Renewal prior authorization duration365 days (12 months)
    Standard renewal frequency

    Prior Authorization, Documentation, and Billing Guidance

    Prior Authorization

    Obtain prior authorization — validity and site-of-care

    Prior authorization is required for Cimzia. Initial approvals are provided for 6 months (180 days); renewals may be authorized every 12 months (365 days). Site-of-care specialty infusion program requirements apply when relevant (refer to Moda Site of Care Policy).

    • Initial prior authorization validity: 180 days.
    • Renewal prior authorization validity: 365 days.
    • Site-of-care specialty infusion program requirements must be met when applicable.
    Prior Authorization

    Prior authorization required — document prior trials or continuation

    Submit a prior authorization request demonstrating the member meets indication-specific criteria and that the member has had prior trial and inadequate response, contraindication, or intolerance to required alternative agents (requirements differ by indication and by Commercial vs Medicaid). Continuing treatment is an alternative pathway.

    • Provide documentation of prior therapy trials (3-month trials for most alternatives unless otherwise noted).

    Drug Background and Context

    Certolizumab pegol (Cimzia) is an anti‑TNF biologic indicated for multiple inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. The policy requires objective baseline assessment and prior‑therapy documentation, and specifies dosing schedules, administration, and prior authorization requirements to ensure appropriate and safe use.

    Definitions, Response Criteria, and NQTLs

    HCPCS billable units — maximum billable units per dose and over time
    Per-dose maximumsPer dosing table: 400 billable units (common maximum per single dose for adult loading/maintenance where applicable)
    pJIA maintenance200 billable units every other week for pJIA maintenance dosing
    All-other-indications maintenance400 billable units every 4 weeks for most adult indications (alternative: 200 mg every other week)
    ICI-related toxicityManagement of ICI-related toxicities: 400 billable units x 1 dose maximum
    Contraindications to phototherapy — examples
    Xeroderma pigmentosumListed as a contraindication to phototherapy (PUVA/UVB)
    Policy Summary
    PayerModa Health
    PolicyCimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria
    Policy CodePolicy M-0028
    Change TypeNo material changes
    Effective DateMar 3, 2026
    Last ReviewMar 3, 2026
    Next Review DateMar 3, 2026
    Key ActionObtain prior authorization with documentation of baseline objective disease severity, required prior therapy trials or contraindications, and required pre-treatment screening (HBV and latent TB) before initiating Cimzia.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsBilling, Codes, and Authorization DurationsPrior Authorization, Documentation, and Billing GuidanceDrug Background and ContextDefinitions, Response Criteria, and NQTLs
    Commercial step:
    For Commercial members: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, tofacitinib, upadacitinib, or tocilizumab SC; OR member is continuing treatment.
    3 months (where applicable)

    Commercial step therapy

    Medicaid step: For Medicaid members: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, or tocilizumab SC; OR member is continuing treatment.3 months (where applicable)

    Medicaid step therapy

    Commercial step therapy for CD

    Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab or ustekinumab SC; OR member is continuing treatment.3 months

    Medicaid step therapy for CD

    Commercial step therapy for PsA

    Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, or ustekinumab SC; OR member is continuing treatment.3 months

    Medicaid step therapy for PsA

    Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, or secukinumab; OR member is continuing treatment.3 months

    Medicaid step therapy for AS

    Dosing: Loading doses: 400 units subcutaneously at weeks 0, 2, and 4; maintenance: 200 units subcutaneously every other week.

    pJIA dosing limits

    AS_response: Ankylosing Spondylitis: improvement in back pain, function, morning stiffness, or scoring tools (e.g., ASDAS improvement ≥1.1 or BASDAI improvement ≥2).ASDAS >=1.1 or BASDAI >=2
    pJIA_response: pJIA: improvement in signs/symptoms vs baseline (e.g., tender/swollen joints, CRP, patient global), or improvement on JADAS or ACR-Pedi 30 (≥30% improvement in 3 of 6 variables).ACR-Pedi 30 >=30%
    nr-axSpA_response: nr-axSpA: improvement in back pain, function, CRP, or scoring tools (e.g., ASDAS improvement ≥1.1, ASDAS-MI, BASDAI improvement ≥2, or ASAS40).ASDAS >=1.1 or BASDAI >=2 or ASAS40
    200 mg Q2W
    Authorizations may be renewed every 12 months unless otherwise specified
    ExceptionSee indication-specific rules (e.g., some indications may not be renewed)
    Plaque Psoriasis severity thresholds — inv-31
    Severity threshold — BSAInvolvement of at least 10% body surface area (BSA)
    Severity threshold — PASIPsoriasis Area and Severity Index (PASI) score ≥10
    Severity threshold — functional/psychosocial impactIncapacitation or serious emotional consequences due to plaque location or intractable pruritis
    Minimum disease durationDocumented moderate to severe plaque psoriasis for at least 6 months
    Prior therapy requirement summaryFailure or intolerance to topical agents (≥4 weeks), at least one non-biologic systemic agent (≥3 months), and phototherapy (≥3 months) unless already on biologic/targeted therapy or BSA >10%
    Psoriasis dosing note — inv-32
    Weight-based initiation guidanceMembers with body weight ≤90 kg should initiate at the lower dosing regimen: 200 mg every other week plus loading doses
    Applies toPlaque psoriasis patients (note in dosing section for body weight ≤90 kg)
    RationaleSpecified in the plaque psoriasis initial therapy criteria as dosing note for lower-weight patients
    HCPCS billable units — inv-55
    HCPCS unit definition (per policy dosing tables)Billable units referenced correspond to mg-equivalent dosing limits for indications (e.g., 200 and 400 billable units)
    Common per-dose maximum400 billable units per dose (used for loading doses and some maintenance regimens)
    pJIA maintenance unit200 billable units every other week for pJIA maintenance
    All other indications maintenance400 billable units every 4 weeks (maintenance for most adult indications)
    Immune checkpoint toxicity billingManagement of immune checkpoint inhibitor-related toxicities: 400 billable units x 1 dose
  1. Indicate if the request is for continued treatment for a member already established on biologic/targeted synthetic therapy.
  2. Note

    Include dosing and response documentation; bill correctly

    For prior authorization, document indication-specific baseline and response measures and confirm adherence to required loading and maintenance dosing (e.g., receipt of three loading doses when applicable). If provider-administered, billing may use HCPCS J0717 per policy.

    • Document objective baseline measures and evidence of response on renewal (see disease-specific tools).
    • Document receipt of loading doses and maintenance dosing as specified (e.g., 400 mg at weeks 0,2,4 then maintenance 200 mg Q2W or 400 mg Q4W).
    • If drug is administered by provider, bill using J0717 (injection, certolizumab pegol, 1 mg) where appropriate.
    Note

    PA applied after NQTL review (indication, safety, cost)

    Prior authorization is applied after consideration of NQTL factors; the NQTL checklist shows indication, safety/efficacy, and drug cost were reasons to consider prior authorization for this drug.

    • NQTL factors considered: indication (Yes), safety and efficacy (Yes), cost (Yes), potential for misuse/abuse (No).
    Documentation Required

    Submit Appendix 1 ICD-10 code; follow Medicare guidance where applicable

    When requesting coverage or submitting claims, include an appropriate ICD-10 diagnosis code from Appendix 1. For Medicare members, applicable NCD/LCD/LCA or Medicare contractor requirements may supersede — reference CMS/Medicare guidance where relevant.

    • Use an Appendix 1 ICD-10 code that matches the member's diagnosis on prior authorization and claim submissions.
    • Check Medicare NCD/LCD/LCA guidance for Part B where applicable; Medicare Part B covered diagnosis codes are listed as N/A in this policy but contractor rules may apply.
    Step Therapy

    Document required prior agent trials per indication

    For each indication, provide documentation that required prior agent trials were completed and that the member had inadequate response, contraindication, or intolerance to those agents (specific lists differ by indication and by Commercial vs Medicaid).

    • Commercial and Medicaid required alternative agent lists differ by indication — include which agent(s) were trialed and trial duration (commonly 3 months).
    • If member is already established on biologic/targeted synthetic therapy, document that status as an alternative to step therapy.
    Step Therapy

    Confirm step-therapy trials and duration (usually 3 months)

    Ensure documentation shows the member tried and had inadequate response, contraindication, or intolerance to specified alternative agents for the required trial period (typically a 3-month trial) before approving Cimzia, unless the member is already established on therapy.

    • Typical required trial duration for alternatives is 3 months unless otherwise specified.
    • Document specific alternative agent(s) tried and clinical reason for failure/intolerance/contraindication.
    Documentation Required

    Psoriasis dose escalation requires documented initial response and dosing milestones

    For plaque psoriasis, dose escalation is permitted only after the patient has shown initial response, received the three specified loading doses and at least one maintenance dose, and demonstrated response by treatment week 6 with subsequent loss of response to justify escalation.

    • Required: documentation of initial response, receipt of loading doses (400 mg at weeks 0, 2, 4) and at least one maintenance dose before escalation.
    • Dose escalation limited to maximum dose/frequency specified in the dosing section and considered case-by-case.
    Note

    Step therapy sequences: not fully specified here — see indication sections

    This section does not list a step-by-step sequence for step therapy; the NQTL checklist explains factors considered for PA design but specific step therapy sequences are provided within indication-specific criteria elsewhere in the policy.

    • Review indication-specific sections for the precise alternative agents required per member type (Commercial vs Medicaid).
    Documentation Required

    Document baseline disease severity with objective measures

    Document baseline disease severity using an objective tool and evidence of moderate-to-severe (or active) disease for the indicated condition when submitting a PA request.

    • Use disease-specific objective measures (e.g., DAS28, JADAS, PASI, CRP, MRI findings) as described in the indication-specific criteria.
    • Include documented assessment confirming moderate-to-severe or active disease.
    Documentation Required

    Pre-treatment screening: HBV, TB, vaccinations, concurrent therapy

    Provide pre-treatment screening documentation: hepatitis B virus (HBV) screening, latent tuberculosis (TB) screening with plan for ongoing monitoring, verification of up-to-date vaccinations, and confirmation the member is not receiving another biologic or targeted synthetic therapy.

    • HBV screening must be completed prior to initiating treatment.
    • Latent TB screening must be completed prior to initiating treatment with ongoing monitoring during therapy.
    • Confirm member has not recently received live vaccines and is up to date with age-appropriate vaccinations.
    Documentation Required

    Submit baseline and objective response data at renewal

    For renewals, provide objective documentation of disease response compared to baseline using indication-specific tools (e.g., DAS28 or ACR20 for RA; Harvey‑Bradshaw Index or CRP for Crohn's; JADAS or ACR‑Pedi for pJIA; ASDAS/BASDAI or ASAS40 for nr-axSpA; PASI/PGA/BSA for PsO).

    • Include the baseline objective measure and the measure at renewal to demonstrate improvement.
    • Renewal requires meeting the renewal criteria and absence of unacceptable toxicity.
    Documentation Required

    For PsO escalation, document loading doses, initial response, and maintenance dosing

    When considering psoriasis dose escalation, document initial clinical response and confirm the member received the three loading doses and at least one maintenance dose at the specified intervals prior to escalation.

    • Document timing and dosing of the three loading doses (400 mg at weeks 0, 2, 4) and at least one maintenance dose.
    • Show initial response and subsequent loss of response by treatment week 6 to support escalation.
    Documentation Required

    Document the required diagnosis using Appendix 1 ICD-10 codes

    Include the member's ICD-10 diagnosis code from Appendix 1 on the prior authorization and claim submissions; Appendix 1 contains the covered diagnosis codes (e.g., K50.x, L40.x, M05.x series).

    • Use an Appendix 1 code that matches the clinical diagnosis exactly when requesting coverage.
    • Appendix 1 lists extensive RA, juvenile arthritis, axial spondyloarthritis, psoriasis, and Crohn's disease codes.
    Documentation Required

    Require submission of Appendix 1 ICD-10 code on PA/claim

    When requesting coverage, submit the member's ICD-10 diagnosis code from Appendix 1 with the PA request; the appendix contains the covered diagnosis codes for rheumatoid and juvenile arthritis and related spondyloarthritis and dermatologic conditions.

    • Ensure the submitted diagnosis code is listed in Appendix 1 to avoid coverage denial.
    • If the diagnosis is not listed in Appendix 1, coverage may be denied (see diagnosis-code based denial risk).
    Denial Risk

    Clinical exclusions that may trigger denial (infection, vaccines, concurrent biologics)

    Do not initiate or continue Cimzia in the presence of active infection, recent live vaccines, lack of required TB screening/monitoring, or if the member is receiving another biologic/targeted synthetic therapy — these clinical exclusions can trigger denial.

    • Active infection or clinically important localized infections are exclusions to initiation.
    • Members must not receive live vaccines immediately prior to or during therapy.
    • Concurrent treatment with another biologic or targeted synthetic therapy is not allowed.
    Denial Risk

    Renewal denials: expired authorization or unacceptable toxicity

    Renewal may be denied if the authorization duration has been exceeded or if there is unacceptable toxicity from the drug — examples include severe hypersensitivity, serious infection, heart failure, lupus‑like syndrome, demyelinating disease, cytopenias, malignancy, or hepatitis B reactivation.

    • Verify authorization duration and that renewal criteria are met before submitting a renewal.
    • Document absence of unacceptable drug-related toxicity to support renewal.
    Billing Rule

    Avoid billing misuse of J0717 for self-administered doses

    Do not bill J0717 when the product is self-administered; J0717 is for physician‑supervised administration and inappropriate use of this code for self‑administered doses may trigger claim denial.

    • J0717 = Injection, certolizumab pegol, 1 mg; 1 billable unit = 1 mg.
    • Use J0717 only when the drug is administered under direct physician supervision per Medicare guidance; it is not for self-administered product.
    Note

    NQTL findings that supported prior authorization

    Prior authorization and utilization management were designed after reviewing NQTL factors; indication, safety/efficacy, and cost supported consideration of PA for Cimzia and may trigger PA requirements.

    • NQTL checklist: indication (Yes), safety/efficacy (Yes), cost (Yes) — these drove PA design.
    • Utilization management methods are applied comparably across MH/SUD and M/S drugs per the appendix.
    Denial Risk

    Diagnosis-code based denial risk — use Appendix 1 codes

    Use of Cimzia for a diagnosis not listed in Appendix 1 may lead to coverage denial if no applicable Appendix 1 ICD-10 code is submitted with the request or claim.

    • Confirm the member's diagnosis code is included in Appendix 1; otherwise, coverage may be denied.
    • Appendix 1 contains extensive lists of covered codes for RA, pJIA, nr-axSpA, PsO, and Crohn's disease.
    Other photosensitive genodermatosesExamples include trichothiodystrophy, Cockayne syndrome, Bloom syndrome, Rothmund-Thomson syndrome (UVB only)
    Pregnancy or lactationPregnancy or lactation is a contraindication to PUVA phototherapy
    Lupus erythematosusListed as a contraindication to phototherapy
    History of photosensitivity or skin cancerHistory of photosensitivity diseases, melanoma, non-melanoma skin cancer, or extensive solar damage may contraindicate phototherapy
    pJIA response — indicators of improvement
    Joint counts improvementImprovement in number of tender and swollen joint counts compared to baseline
    CRP reductionReduction in C‑reactive protein (CRP) from baseline
    Disease activity scoresImprovement on a disease activity tool such as JADAS or ACR‑Pedi 30 (≥30% improvement in 3 of 6 variables)
    Patient global assessmentImprovement in patient global assessment compared to baseline
    nr-axSpA response — improvement measures
    Back pain and functionImprovement in total back pain and physical function compared to baseline
    CRP reductionReduction in C‑reactive protein (CRP)
    ASDAS/BASDAI/ASAS thresholdsStandardized improvements such as ≥1.1 improvement on ASDAS, ASDAS‑MI (≥2.0 for major improvement), ≥2 improvement on BASDAI, or ASAS40 response
    Quality of lifeImprovement in ASQoL score from baseline
    PsO response — improvement measures and initial response requirements
    BSA/PASI/PGA targetsResponse may be demonstrated by BSA ≤1%, PASI ≤3, or PGA ≤1 compared to baseline
    Initial response prerequisiteDose escalation is permitted only after shown initial response and receipt of three loading doses plus at least one maintenance dose
    Timing for escalationResponded by treatment week 6 with subsequent loss of response may justify escalation
    Non-Quantitative Treatment Limitations (NQTL)
    DefinitionNQTLs are methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan
    Examples of NQTLsUtilization review and prior authorization are examples of NQTLs used to manage benefit extent/duration
    Factors consideredPolicy NQTL checklist considered indication, safety/efficacy, potential misuse, and drug cost when designing PA
    Appendix 1 — Covered Diagnosis Codes (definition)
    DefinitionAppendix 1 is the policy list of covered ICD‑10 diagnosis codes for conditions where Cimzia may be medically necessary
    Use in submissionsProviders should submit an Appendix 1 ICD‑10 code when requesting coverage
    ScopeAppendix contains extensive RA, juvenile arthritis, ankylosing spondylitis, psoriasis and related codes; see full appendix for details
    Appendix 2 — CMS/Medicare guidance
    Medicare guidance sourceMedicare Part B coverage is governed by the Medicare Benefit Policy Manual (Pub. 100‑02), Chapter 15, §50, and applicable NCDs/LCDs/LCAs
    Local/jurisdictional applicabilityNCDs, LCDs, and LCAs may exist and must be followed where applicable; links provided to CMS coverage database
    Medicare Part B codes notePolicy notes Medicare Part B covered diagnosis codes as N/A in this document; existing NCD/LCD/LCA requirements may supersede policy provisions